NASDAQ:DMAC DiaMedica Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding DiaMedica Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.10 +0.19 (+4.86 %) (As of 09/25/2020 12:00 AM ET) Add Compare Share Today's Range$3.87Now: $4.10▼$4.2750-Day Range$3.91MA: $4.70▼$5.7252-Week Range$1.70Now: $4.10▼$8.80Volume30,406 shsAverage Volume59,780 shsMarket Capitalization$76.83 millionP/E RatioN/ADividend YieldN/ABeta2.43 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingDiaMedica Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.33, DiaMedica Therapeutics has a forecasted upside of 249.6% from its current price of $4.10.Amount of Analyst CoverageDiaMedica Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.2 Community Rank Outperform VotesDiaMedica Therapeutics has received 75 “outperform” votes. (Add your “outperform” vote.)Underperform VotesDiaMedica Therapeutics has received 94 “underperform” votes. (Add your “underperform” vote.)Community SentimentDiaMedica Therapeutics has received 55.62% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about DiaMedica Therapeutics and other stocks. Vote “Outperform” if you believe DMAC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DMAC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldDiaMedica Therapeutics does not currently pay a dividend.Dividend GrowthDiaMedica Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DiaMedica Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 12.60% of the stock of DiaMedica Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 16.16% of the stock of DiaMedica Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of DiaMedica Therapeutics is -5.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DiaMedica Therapeutics is -5.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDiaMedica Therapeutics has a P/B Ratio of 6.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.14 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DMAC Previous Symbol CUSIPN/A CIKN/A Webwww.diamedica.com Phone763-312-6755Debt Debt-to-Equity Ratio0.01 Current Ratio10.19 Quick Ratio10.19Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$500,000.00 Price / Sales153.66 Cash FlowN/A Price / Cash FlowN/A Book Value$0.64 per share Price / Book6.41Profitability EPS (Most Recent Fiscal Year)($0.89) Net Income$-10,650,000.00 Net MarginsN/A Return on Equity-93.84% Return on Assets-83.62%Miscellaneous Employees9 Outstanding Shares18,739,000Market Cap$76.83 million Next Earnings Date11/11/2020 (Estimated) OptionableNot Optionable $4.10 +0.19 (+4.86 %) (As of 09/25/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive DMAC News and Ratings via Email Sign-up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter. DiaMedica Therapeutics (NASDAQ:DMAC) Frequently Asked Questions How has DiaMedica Therapeutics' stock price been impacted by Coronavirus (COVID-19)? DiaMedica Therapeutics' stock was trading at $4.00 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DMAC stock has increased by 2.5% and is now trading at $4.10. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of DiaMedica Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for DiaMedica Therapeutics. When is DiaMedica Therapeutics' next earnings date? DiaMedica Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020. View our earnings forecast for DiaMedica Therapeutics. How were DiaMedica Therapeutics' earnings last quarter? DiaMedica Therapeutics Inc (NASDAQ:DMAC) announced its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.02. View DiaMedica Therapeutics' earnings history. What price target have analysts set for DMAC? 3 analysts have issued 12 month price objectives for DiaMedica Therapeutics' stock. Their forecasts range from $14.00 to $15.00. On average, they anticipate DiaMedica Therapeutics' stock price to reach $14.33 in the next year. This suggests a possible upside of 249.6% from the stock's current price. View analysts' price targets for DiaMedica Therapeutics. Are investors shorting DiaMedica Therapeutics? DiaMedica Therapeutics saw a decline in short interest in September. As of September 15th, there was short interest totaling 20,600 shares, a decline of 21.1% from the August 31st total of 26,100 shares. Based on an average daily volume of 52,100 shares, the short-interest ratio is currently 0.4 days. View DiaMedica Therapeutics' Short Interest. Who are some of DiaMedica Therapeutics' key competitors? Some companies that are related to DiaMedica Therapeutics include IMV (IMV), Urovant Sciences (UROV), Cassava Sciences (SAVA), Osmotica Pharmaceuticals (OSMT), Xeris Pharmaceuticals (XERS), Concert Pharmaceuticals (CNCE), Aldeyra Therapeutics (ALDX), Liminal BioSciences (LMNL), Selecta Biosciences (SELB), Paratek Pharmaceuticals (PRTK), Chiasma (CHMA), Aquestive Therapeutics (AQST), Arbutus Biopharma (ABUS), VYNE Therapeutics (VYNE) and Affimed (AFMD). View all competitors. What other stocks do shareholders of DiaMedica Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Vaxart (VXRT), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), Oncolytics Biotech (ONCY), Pfizer (PFE), AbbVie (ABBV), Adamis Pharmaceuticals (ADMP) and Amarin (AMRN). Who are DiaMedica Therapeutics' key executives? DiaMedica Therapeutics' management team includes the following people: Mr. Rick Pauls M.B.A., MBA, Pres, CEO & Director (Age 48)Mr. Scott B. Kellen C.A., CFO & Company Sec. (Age 54)Dr. Todd A. Verdoorn, Chief Scientific Officer (Age 57)Mr. Edward B. Rady, Chief Commercial Advisor (Age 70)Dr. Dennis D. Kim M.D., MBA, Consulting Chief Medical Officer (Age 49) When did DiaMedica Therapeutics IPO? (DMAC) raised $18 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 4,000,000 shares at $4.00-$5.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO. What is DiaMedica Therapeutics' stock symbol? DiaMedica Therapeutics trades on the NASDAQ under the ticker symbol "DMAC." Who are DiaMedica Therapeutics' major shareholders? DiaMedica Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Corriente Advisors LLC (1.42%) and Bank of New York Mellon Corp (0.10%). Company insiders that own DiaMedica Therapeutics stock include Dietrich John Pauls, Harry W Alcorn Jr, Randall Michael Giuffre, Richard D Pilnik and Scott Kellen. View institutional ownership trends for DiaMedica Therapeutics. Which major investors are buying DiaMedica Therapeutics stock? DMAC stock was purchased by a variety of institutional investors in the last quarter, including Corriente Advisors LLC, and Bank of New York Mellon Corp. Company insiders that have bought DiaMedica Therapeutics stock in the last two years include Dietrich John Pauls, Harry W Alcorn Jr, Randall Michael Giuffre, Richard D Pilnik, and Scott Kellen. View insider buying and selling activity for DiaMedica Therapeutics. How do I buy shares of DiaMedica Therapeutics? Shares of DMAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is DiaMedica Therapeutics' stock price today? One share of DMAC stock can currently be purchased for approximately $4.10. How big of a company is DiaMedica Therapeutics? DiaMedica Therapeutics has a market capitalization of $76.83 million and generates $500,000.00 in revenue each year. The company earns $-10,650,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. DiaMedica Therapeutics employs 9 workers across the globe. What is DiaMedica Therapeutics' official website? The official website for DiaMedica Therapeutics is www.diamedica.com. How can I contact DiaMedica Therapeutics? DiaMedica Therapeutics' mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The company can be reached via phone at 763-312-6755 or via email at [email protected] This page was last updated on 9/26/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
